Vijay Singh Ph.D.

Education

1996 - 1997 Vising Scientist, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
1987 - 89 Visiting Associate, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
1984 - 87 Post-doctoral Fellow, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
1983 Ph.D., Central Drug Research Institute, Lucknow (KU), India

Biography

Advanced development of radiation countermeasures, investigations for biomarkers for radiation injury and countermeasure efficacy, mechanism of action of various radiation medical countermeasure
The primary research interests of Dr. Singh’s laboratory are to develop radiation countermeasures for acute radiation syndrome (ARS) following US FDA Animal Rule. His activities for this endeavor can be divided into the following major categories: 1) Development of BIO 300 (genistein) as radiation countermeasure for ARS and delayed effects of acute radiation exposure (DEARE), 2) Development of gamma-tocotrienol for ARS, 3) Role of growth factors in progenitor mobilization and radiomitigation, 4) Identification and validation of biomarkers for radiation injury and countermeasure efficacy, 5) Advanced development of other promising radiation countermeasures using small and large animal models. His laboratory has extensive experience in studying the hematopoietic and gastrointestinal ARS following total-body and partial-body irradiation using animal models, and the effects of various radiation countermeasures on injury and recovery. He has few radiation countermeasures under advanced development which have US Food and Drug Administration Investigational New Drug (IND) status for development under Animal Rule. His objective is to identify and validate non-invasive biomarkers using various omic platforms for radiation injury and countermeasure efficacy.
His laboratory has identified and validated several biomarkers using metabolomics/lipidomics, proteomics, transcriptomics, and miRNA for radiation dose assessment and efficacy of radiation countermeasures. He has also identified a few miRNAs which can distinguish between irradiated versus unirradiated animals. Results of biomarker study using multi-omics approach is encouraging. He collaborates with large number of academic and corporate collaborators in US as well as from other countries. He is recipient of several prestigious award, editorial board member for few reputed journals, and reviewer for research grants of various US agencies of DoD and HHS. He has published 240 papers in high impact journals. He is a member of NATO HFM-359 and teaches during NATO StTARS workshop. He has also been conferred honorary professor from Amity University, India.

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

1. Determination of radiation dose response for the AFRRI LINAC and subsequent non-clinical studies to evaluate potential medical countermeasures as mitigators of hematopoietic and/or low dose GI syndromes (H-ARS; GI-ARS) in an NHP model. Biomedical Advanced Research and Development Authority (BARDA), $8,535,865, 9/15/2015 – 8/31/2023

2. Evaluation of radiation mitigators in nonhuman primates with supportive care. National Institute of Allergy and Infectious Diseases (NIAID), FY 2015 $406,581, FY 2016 $1,226,757, FY17 $1,264,698, FY18 725,333, FY19, 725,000, FY20 $425,000, FY21 $102,500, 9/30/2015 – 8/30/2023

3. Advanced development of BIO 300 for acute radiation syndrome and delayed effects of acute radiation exposure, Congressionally Directed Medical Research Programs/Joint Program Committee 7 (CDMRP/JPC7), $1,195,189, 10/1/2016 – 9/8/2023.

4. Development of BIO 301 to prevent acute radiation syndrome and mitigate the delayed effects of acute radiation exposure. Congressionally Directed Medical Research Programs (CDMRP - JWMRP), $4,720, 276, 9/30/2019 – 12/31/2024.

5. Biomarkers for the development of BIO 301 as a prophylactic radiation countermeasure for the acute and delayed effects of radiation exposure. Joint Program Committee-7, $1,089,459, 4/24/2020 – 4/23/2023

6. Proteomic biomarkers for radiation injury and countermeasure efficacy. NIAID $500,000, 10/01/2021 – 9/30/2026.

7. Development for a novel countermeasure, RadioDefender, as a radioprotector for hematopoietic acute radiation syndrome. Defense Health Agency (through Zymeron Corporation), $1,254,973, 3/25/2022 - 2/6/2024

8. Novel biologic countermeasure for acute radiation syndrome. Defense Health Agency (through Technology Holding), $1,247,939, 6/21/2022 - 10/20/2024

9. Development of BIO 300 Injectable suspension to treat radiation-induced lung injury. CDMRP (through Humanetics Corporation), $720,000, 7/1/2022 – 6/30/2025.

10. Further development of 5-AED (androstenediol, Neumune) for the protection from acute radiation syndrome (ARS). Congressionally Directed Medical Research Programs (CDMRP – JWMRP, Through NSRI), $1,499, 367 POP TBD.

Representative Bibliography

1. Chakraborty N, Dimitrov G, Kanan S, Lawrence A, Moyler C, Gautam A, Fatanmi OO, Wise SY, Carpenter AD, Hammamieh R, Singh VK: Cross-species conserved miRNA as biomarker of radiation injury and to predict fatality risk. PLoS One 19: e0311379, 2024, PMID: 39570918

2. Carpenter AD, Empfield KM, Petrus SA, Fatanmi OO, Wise SY, Tyburski JB, Cheema AK, Singh VK: Metabolomic changes in preterminal serum samples of rhesus macaques exposed to two different lethal doses of total-body gamma-radiation. Sci Rep 14:23930, 2024, PMID: 39397118

3. Tichy A, Carpenter AD, Li Y, Rydlova G, Rehulka P, Markova M, Milanova M, Chmil V, Cheema AK, Singh VK: Radiation signature in plasma metabolome of total-body irradiated nonhuman primates and clinical patients. Intl J Mol Sci 25:9208, 2024, PMID: 39273157

4. Serebrenik AA, Fatanmi OO, Wise SY, Petrus SA, Kaytor MD, Singh, VK: BIO 300 attenuates whole blood transcriptome changes in mice exposed to total-body radiation. Intl J Mol Sci 25:8818, 2024, PMID: 39201502

5. Carpenter AD, Li Y, Wise SY, Fatanmi OO, Petrus SA, Fam CM, Cox GN, Cheema AK, Singh VK: Pharmacokinetic and metabolomic studies with a promising radiation countermeasure BBT-059 (PEGylated interleukin-11), in rhesus nonhuman primates. Radiat Res 202:26-37, 2024, PMID: 38714310

6. Carpenter AD, Fatanmi OO, Wise SY, Tyburski JB, Cheema AK, Singh VK: Proteomic analysis of plasma at the preterminal stage of rhesus nonhuman primates exposed to a lethal total-body dose of gamma-radiation. Sci Rep 14:13571, 2024, PMID: 38866887

7. Singh VK, Wise SY, Fatanmi OO, Petrus SA, Carpenter CC, Lugo-Roman LA, Lee SH, Hauer-Jensen M, Seed TM: Pathology of acute sub-lethal or near-lethal irradiation of nonhuman primates prophylaxed with the nutraceutical, gamma tocotrienol. Sci Rep 14:13315, 2024, PMID: 38858439

8. Carpenter AD, Li Y, Fatanmi OO, Wise SY, Petrus SA, Janocha BL, Cheema AK, Singh VK: Metabolomic profiles in tissues of nonhuman primates exposed to total- or partial-body radiation. Radiat Res 201:371-383, 2024, PMID: 38253059

9. Singh VK, Wise SY, Fatanmi OO, Petrus SA, Carpenter AD, Lee SH, Hauer-Jensen M, Seed TM: Histopathological studies of nonhuman primates exposed to supralethal doses of total- or partial-body radiation: Influence of a medical countermeasure, gamma-tocotrienol. Sci Rep 14:5757, 2024, PMID: 38459144

10. Russ E, Fatanmi OO, Wise SY, Carpenter AD, Maniar M, Iordanskiy S, Singh VK: Serum microRNA profile of rhesus macaques following ionizing radiation exposure and treatment with a medical countermeasure, Ex-Rad. Sci Rep 14:4518, 2024, PMID: 38402257